Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

1.650 -0.200 (-10.81%)
Official Closing Price Updated: 7:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 406,064
Open 1.700
Bid (Size) 1.650 (10)
Ask (Size) 1.780 (4)
Prev. Close 1.850
Today's Range 1.630 - 1.740
52wk Range 1.525 - 20.00
Shares Outstanding 13,797,242
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives NYSE Noncompliance Notice Over Market Cap and Equity Levels
Via Investor Brand Network
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
From Annovis Bio Inc.
Via GlobeNewswire

Performance

YTD
-67.7%
-67.7%
1 Month
-7.8%
-7.8%
3 Month
-67.5%
-67.5%
6 Month
-79.5%
-79.5%
1 Year
-86.2%
-86.2%

More News

Read More
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Late-Stage Alzheimer’s and Parkinson’s Data at AD/PD 2025
Via Investor Brand Network
Ongoing Trial Seeks to Avert Alzheimer’s Decades Before it Strikes
Via Investor Brand Network
Study Uncovers Link Between Gut Infection and Alzheimer’s Disease
Via Investor Brand Network
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer’s and Parkinson’s Pipeline, Launches Pivotal Phase 3 Trial
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
The Brain’s ‘Cleanup Crew’ Could Hold the Key to Alzheimer’s Treatment, Study Shows
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present at Alzheimer’s & Parkinson’s Drug Development Summit
Via Investor Brand Network
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
From Annovis Bio Inc.
Via GlobeNewswire
Scientists Say Brain Stimulations Hold Potential in Treating Anxiety in Parkinson’s Sufferers
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development
Via Investor Brand Network
Top movers in Monday's session
Via Chartmill
Keep an eye on the top gainers and losers in Monday's session.
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session.
Via Chartmill
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $21 Million Public Offering
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
US Announces Plan to Combat Parkinson’s Disease Across the Country
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’
Via Investor Brand Network

Frequently Asked Questions

Is Annovis Bio, Inc. Common Stock publicly traded?
Yes, Annovis Bio, Inc. Common Stock is publicly traded.
What exchange does Annovis Bio, Inc. Common Stock trade on?
Annovis Bio, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Annovis Bio, Inc. Common Stock?
The ticker symbol for Annovis Bio, Inc. Common Stock is ANVS on the New York Stock Exchange
What is the current price of Annovis Bio, Inc. Common Stock?
The current price of Annovis Bio, Inc. Common Stock is 1.650
When was Annovis Bio, Inc. Common Stock last traded?
The last trade of Annovis Bio, Inc. Common Stock was at 03/28/25 07:00 PM ET
What is the market capitalization of Annovis Bio, Inc. Common Stock?
The market capitalization of Annovis Bio, Inc. Common Stock is 22.77M
How many shares of Annovis Bio, Inc. Common Stock are outstanding?
Annovis Bio, Inc. Common Stock has 23M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.